AI assistant
HAEMONETICS CORP — Director's Dealing 2011
Jan 27, 2011
31565_dirs_2011-01-27_40df87bb-32da-41e5-8e95-f6649bc72b8a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2011-01-26
Reporting Person: Nighan Warren JR (VP WW Q&R Affairs)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-01-26 | Common Stock | A | 1514.0 | $0.01 | Acquired | 1514.0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-01-26 | Non-Qualified Stock Option (right to buy) | $59.43 | A | 12514.0 | Acquired | 2018-01-26 | Common Stock (12514.0) | Direct |
Footnotes
F1: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.
F2: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.
F3: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.